Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on August 21, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Gossamer Bio established Series A-1, Series A-2 and Series A-3 preferred stock classes.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Gossamer Bio established Series A-1, Series A-2 and Series A-3 preferred stock classes
- Investor-relevant rights and terms reside in Exhibits 3.1, 3.2 and 3.3
- Multiple preferred series may affect capital structure and common-stockholder rights
Item 7.01 · Regulation FD Disclosure
- Boilerplate Item 7.01 disclosure language only
- No substantive operating, financial, or strategic information for investors
Item EX-99.1 · Exhibit EX-99.1
- Up to $250M financing funds seralutinib development through potential FDA approval, reducing near-term financing risk
- $25M initial closing expected August 24, 2026, plus $125M committed upon FDA acceptance of the PAH NDA
- Additional warrants could generate up to $100M upon FDA approval at a $0.187 exercise price
- Funding depends on regulatory milestones and stockholder approval, creating execution and dilution risks
- Proceeds expected to fund operations into 2028, including PAH and PH-ILD development and commercialization preparation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.